Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PHYX-001
- Development stage
- Preclinical
- Lead developer
- Phytanix
- Modality
- Small Molecules
01
Overview
PHYX-001 is a potassium channel modulator developed for central nervous system (CNS) diseases. Its mechanism of action is similar to that of XEN1101 and BHV-7000, both of which are known as next-generation potassium channel modulators with anticonvulsant properties. The drug was initially developed by Phytanix and later became part of the pipeline following the merger with Protagenic Therapeutics. PHYX-001 is being explored for indications within nervous system diseases, including potential applications in obesity and metabolic dysfunction, though its highest phase of development remains unknown as of June 2025[1][2][3][4].
02
Targets
KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2)KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)
Beyond the preview
Go deeper on PHYX-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PHYX-001.